Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients

被引:35
|
作者
Hall, Isaac E. [1 ,2 ]
Stern, Edward P. [3 ]
Cantley, Lloyd G. [1 ]
Elias, Jack A. [4 ]
Parikh, Chirag R. [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Program Appl Translat Res, New Haven, CT 06510 USA
[3] Royal Free London NHS Fdn Trust, Ctr Nephrol, Univ Coll London, London, England
[4] Brown Univ, Div Biol & Med, Providence, RI 02912 USA
来源
BMC NEPHROLOGY | 2014年 / 15卷
基金
美国国家卫生研究院;
关键词
Acute kidney injury; Biomarker; BRP-39; Chitinase; 3-like-1; Net reclassification improvement; YKL-40; CLINICAL-APPLICATIONS; CARDIAC-SURGERY; POOR OUTCOMES; BIOMARKERS; AKI; METAANALYSIS; DIALYSIS; MARKERS; DISEASE; VALUES;
D O I
10.1186/1471-2369-15-133
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: A translational study in renal transplantation suggested YKL-40, a chitinase 3-like-1 gene product, plays an important role in acute kidney injury (AKI) and repair, but data are lacking about this protein in urine from native human kidneys. Methods: This is an ancillary study to a single-center, prospective observational cohort of patients with clinically-defined AKI according to AKI Network serum creatinine criteria. We determined the association of YKL -40 >= 5 ng/ml, alone or combined with neutrophil gelatinase-associated lipocalin (NGAL), in urine collected on the first day of AKI with a clinically important composite outcome (progression to higher AKI stage and/or in-hospital death). Results: YKL-40 was detectable in all 249 patients, but urinary concentrations were considerably lower than in previously measured deceased-donor kidney transplant recipients. Seventy-two patients (29%) progressed or died in-hospital, and YKL-40 >= 5 ng/ml had an adjusted odds ratio (95% confidence interval) for the outcome of 3.4 (1.5-7.7). The addition of YKL-40 to a clinical model for predicting the outcome resulted in a continuous net reclassification improvement of 29% (P = 0.04). In patients at high risk for the outcome based on NGAL concentrations in the upper quartile, YKL-40 further partitioned the cohort into moderate-risk and very high-risk groups. Conclusions: Urine YKL-40 is associated with AKI progression and/or death in hospitalized patients and improves clinically determined risk reclassification. Combining YKL-40 with other AKI biomarkers like NGAL may further delineate progression risk, though additional studies are needed to determine whether YKL-40 has general applicability and to define its association with longer-term outcomes in AKI.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
    Mylin, Anne K.
    Rasmussen, Thomas
    Johansen, Julia S.
    Knudsen, Lene M.
    Norgaard, Peter H.
    Lenhoff, Stig
    Dahl, Inger M. S.
    Johnsen, Hans E.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (05) : 416 - 424
  • [22] YKL-40 Expression in Traumatic Brain Injury: An Initial Analysis
    Bonneh-Barkay, Dafna
    Zagadailov, Pavel
    Zou, Huichao
    Niyonkuru, Christian
    Figley, Matthew
    Starkey, Adam
    Wang, Guoji
    Bissel, Stephanie J.
    Wiley, Clayton A.
    Wagner, Amy K.
    JOURNAL OF NEUROTRAUMA, 2010, 27 (07) : 1215 - 1223
  • [23] Serum YKL-40 is increased in patients with hepatic fibrosis
    Johansen, JS
    Christoffersen, P
    Moller, S
    Price, PA
    Henriksen, JH
    Garbarsch, C
    Bendtsen, F
    JOURNAL OF HEPATOLOGY, 2000, 32 (06) : 911 - 920
  • [24] The value of YKL-40 in ischemic heart disease patients
    Doaa S. E. Zaky
    Fatma M. Mabrouk
    Eman R. Zaki
    Olfat M. Hendy
    The Egyptian Journal of Internal Medicine, 2016, 28 (2) : 71 - 77
  • [25] Novel Inflammatory Marker in Dialysis Patients: YKL-40
    Okyay, Gulay Ulusal
    Er, Ramazan Erdem
    Tekbudak, Merve Yasemin
    Pasaoglu, Ozge
    Inal, Salih
    Onec, Kursad
    Pasaoglu, Hatice
    Altok, Kadriye
    Derici, Ulver
    Erten, Yasemin
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (02) : 193 - 201
  • [26] Acute kidney disease in hospitalized acute kidney injury patients
    Yan, Ping
    Duan, Xiang-Jie
    Liu, Yu
    Wu, Xi
    Zhang, Ning-Ya
    Yuan, Fang
    Tang, Hao
    Liu, Qian
    Deng, Ying-Hao
    Wang, Hong-Shen
    Wang, Mei
    Duan, Shao-bin
    PEERJ, 2021, 9
  • [27] YKL-40 levels in patients with coronary artery ectasia
    Balta, Sevket
    Demirkol, Sait
    Kucuk, Ugur
    Demir, Mustafa
    Arslan, Zekeriya
    Unlu, Murat
    ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, 2014, 14 (01): : 97 - 98
  • [28] Serum YKL-40 in patients with early polyarthritis.
    Johansen, JS
    Klarlund, M
    Price, PA
    Skiodt, H
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S311 - S311
  • [29] Increased YKL-40 expression in patients with carotid atherosclerosis
    Michelsen, Annika E.
    Rathcke, Camilla N.
    Skjelland, Mona
    Holm, Sverre
    Ranheim, Trine
    Krohg-Sorensen, Kirsten
    Klingvall, Marit F.
    Brosstad, Frank
    Oie, Erik
    Vestergaard, Henrik
    Aukrust, Pal
    Halvorsen, Bente
    ATHEROSCLEROSIS, 2010, 211 (02) : 589 - 595
  • [30] YKL-40 as a predictor of mortality after acute coronary syndrome
    Sciborski, Krzysztof
    Gierlotka, Marek
    Protasiewicz, Marcin
    Karolko, Bozena
    Negrusz-Kawecka, Marta
    Kuliczkowski, Wiktor
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2020, 130 (04): : 343 - 345